The reverse vesicle composition of the present invention includes (A) a sphingosine represented by formula (1) (wherein R 1 represents a C4 to C30 linear alkyl group which may be substituted by a hydroxyl group, a carbonyl group, or an amino group; Y represents a methylene group, a methine group, or an oxygen atom; each of X 1 , X 2 , and X 3 represents a hydrogen atom, a hydroxyl group, or an acetoxy group; X 4 represents a hydrogen atom, an acetyl group, or a glyceryl group, or forms an oxo group together with the adjacent oxygen atom (wherein when Y is a methine group, one of X 1 and X 2 is a hydrogen atom, and the other is absent, and when X 4 forms an oxo group, X 3 is absent); each of R 2 and R 3 represents a hydrogen atom, a hydroxyl group, a hydroxyethyl group, or an acetoxymethyl group; a is a number of 2 or 3; each of (R) a represents a hydrogen atom, an amidino group, or a linear-chain alkyl group optionally having a substituent selected from among a hydroxyl group, a hydroxyalkoxy group, an alkoxy group, and an acetoxy group and containing 1 to 8 carbon atoms in total; and the broken line represents an optional unsaturated bond), (B) a C16 to C30 fatty acid, (C) a hydrocarbon oil, (D) an ester oil which is in liquid form at 25°C, and (F) water, wherein the ratio by mass of ingredient (C) to ingredient (D) satisfies the following relationship: 1‰¤(C)/(D)